Paralympic Champion Josh Turek Wins Democratic Senate Primary in Iowa
By
Shaun Heasley
Summary
Iowa state Rep. Josh Turek, a Paralympic champion with spina bifida, has won the Democratic nomination for a U.S. Senate seat previously held by Sen. Tom Harkin, a key architect of the Americans with Disabilities Act. Turek, who uses a wheelchair and won bronze medals in Paralympic basketball, is running on a platform of protecting Social Security, Medicare, and Medicaid, and expanding voting access. His candidacy has drawn national attention as a historic opportunity for disability representation in the Senate, though he faces a tough general election race in a Republican-leaning state.
Source
Key quotes
· 3 pulledI think it's a testament to the fact that Iowans are looking for someone who's going to fight for them, who's going to work hard for them, and who's going to be a voice for all Iowans.
I think it's a testament to the fact that Iowans are looking for someone who's going to fight for them, who's going to work hard for them, and who's going to be a voice for all Iowans.
I think it's a testament to the fact that Iowans are looking for someone who's going to fight for them, who's going to work hard for them, and who's going to be a voice for all Iowans.
You might also wanna read
Disability Golf Champion Brad Smith Calls for Paralympic Inclusion
Disability golf champion Brad Smith advocates for the inclusion of the sport in future Paralympic Games. Smith, who had his right leg amputa

Elections: Information for Voters With Disabilities

3 Bloomington-Normal athletes place at Special Olympics USA

Democrats to choose between progressive and establishment candidate in Michigan as McMorrow drops out of race – US politics live
Team Vermont wins gold, 16 medals at Special Olympics USA Games
Former Leicester Tigers Player Transforms into Para-Canoeist After Tragic Accident
Former Leicester Tigers rugby player Taylor Gough, paralyzed from the chest down in a car crash, has transitioned to become a successful par

Comments
Sign in to join the conversation.
No comments yet. Be the first.